1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

APA Update: New Antidepressants Elbow Into Crowded Market

 
• By Emily Hayes

Lundbeck/Takeda unveil pivotal trial data for Brintellix (vortioxetine) in major depression, while Forest pooled analyses shed more light on levomilnacipran in subgroups. Docs don’t think the new drugs are differentiated, but since antidepressant response is so quirky, the prescribing door is still open.

SAN FRANCISCO – Takeda Pharmaceutical Co. Ltd./Lundbeck Inc.’s Brintellix and Forest Laboratories Inc.’s levomilnacipran may struggle to stand out in a crowded market based on the latest data releases. But considering how quirky treatment response is for depression and the extent of unmet need, new antidepressants could still find their feet.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D